Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
New England Biolabs (NEB®) today announces the release of the NEBNext Flu A Integrated Indexing Primer Module (NEB #E3436), ...
Novartis phase III trial for next-generation malaria treatment KLU156 meets primary endpoint, with potential to combat antimalarial resistance: Basel Friday, November 14, 2025, 09 ...
The review also calls for embedding diagnostics within the One Health framework, which integrates human, animal, and ...
Despite strong evidence for metronidazole, amoebiasis persists as a global burden, highlighting gaps in diagnostics and ...
Novartis' GanLum met key Phase 3 goals, showing strong efficacy and safety in malaria patients, including against resistant ...
Novartis (NVS) stock is in focus as the company announces a late-stage trial win for its new malaria drug GanLum developed ...
Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...
This manuscript reports on the application of ribosome profiling (EZRA-seq and eRF1-seq) combined with massively parallel reporter assays to identify and characterize a GA-rich element associated with ...
Swiss pharma giant Novartis has announced positive results from KALUMA, a Phase III study for new malaria treatment KLU156 ...
Health authorities urge clinicians to check vaccination status and watch for chronic or worsening wounds, especially in ...
The blast occurred while personnel were handling the explosive material that had been brought from Haryana's Faridabad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback